roluperidone + olanzapine

**Roluperidone + olanzapine** is an investigational drug combination consisting of *roluperidone*, a novel psychotropic agent in development for negative symptoms of schizophrenia, and *olanzapine*, a well-established atypical antipsychotic. The combination is being evaluated for its safety, tolerability, pharmacodynamics, and pharmacokinetics when co-administered in adult subjects with moderate to severe negative symptoms of schizophrenia. Roluperidone acts as an antagonist at serotonin 5-HT2A, sigma2, and α1A-adrenergic receptors, whereas olanzapine exerts its antipsychotic effects primarily as an antagonist at dopamine D2 and serotonin 5-HT2A receptors, with additional activity at histamine H1, muscarinic, and adrenergic receptors. The combination is under clinical investigation to assess if co-administration improves symptom control and tolerability compared to monotherapy, and to provide clinical guidance for potential off-label use in schizophrenia treatment[1][3].